Cobalis Files Form of Order with US Bankruptcy Court Signaling Emergence from Bankruptcy

Cobalis Files Form of Order with US Bankruptcy Court Signaling Emergence from Bankruptcy
 
IRVINE, Calif., May 26 /PRNewswire/ -- Cobalis Corp (Pink Sheets: CLSC) announced today that the Company's attorneys have submitted a Form of Order consistent with the United States Bankruptcy Court's ruling of April 7, 2010 confirming the debtor's plan of reorganization.

Upon entry of the Order by the Court, Cobalis Corp will have officially emerged from bankruptcy, and will immediately commence the launch of its long-awaited national marketing plans to bring its flagship anti-allergy product PreHistin® to market.

ABOUT COBALIS CORP--PREHISTIN®

Cobalis Corp. is a specialty pharmaceutical, nutraceutical and preventive healthcare product development and marketing company. Its flagship product, PreHistin®, The World's FIRST Pre-HistamineTM, is designed to mitigate overproduction of IgE levels and restore a normal response to seasonal and year-round indoor and outdoor allergens. PreHistin® is available without prescription for both long-term and daily use.

For PreHistin® product information and ordering please visit at www.PreHistin.com or call toll free 1-877-4POLLEN. For additional company information please visit the corporate website at www.Cobalis.com .

Suggested Articles

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.

The series B positions ex-AveXis executives to build a biotech with a broad gene therapy pipeline and infrastructure to match.

A variant of the ACE2 receptor could work as a COVID-19 therapeutic by drawing the virus away from healthy cells, scientists reported.